<DOC>
	<DOCNO>NCT01697267</DOCNO>
	<brief_summary>Rituximab establish effective drug anti-neutrophil cytoplasmic antibody ( ANCA ) vasculitis follow major European US trial report 2010 . After time , effect wear disease return . This occur least half patient within 2 year receive Rituximab . A preliminary study Cambridge suggest repeat rituximab every six month stops disease return safe . The RITAZAREM trial find whether repeat rituximab stop vasculitis return whether work well old treatment , azathioprine methotrexate . It also tell u long patient remain well repeat rituximab treatment stop , repeat rituximab safe . We also learn useful information effect rituximab quality life economic measure . The trial result help decide best treatment future patient vasculitis initially treat rituximab . RITAZAREM aim recruit patient establish ANCA vasculitis whose disease come back 'relapsing vasculitis ' . All patient treat rituximab steroid anticipate respond well . If disease reasonable control four month , treatment either rituximab ( single dose ever four month two year ) azathioprine tablet choose randomly . The patient rituximab azathioprine group compare . Patients trial four year . The study design member European Vasculitis Study group ( EUVAS ) Vasculitis Clinical Research Consortium ( VCRC ) . It include 190 participant 30 hospital Europe , USA , Australia Mexico . RITAZAREM fund Arthritis Research UK , U.S. National Institutes Health Roche/Genentech .</brief_summary>
	<brief_title>Rituximab Vasculitis Maintenance Study</brief_title>
	<detailed_description>Patients recruit time relapse . All receive rituximab 375 mg/m2/week x 4 glucocorticoid . Those patient achieve disease control ( BVAS/WG ≤ 1 daily prednisone dose ≤ 10 mg ) month 4 randomise rituximab control remission maintenance group . Treatment protocolised entire duration study , common close date , final patient recruit complete 36 month within study patient complete 48 month study whichever sooner . Patients rituximab arm receive treatment month 20 , azathioprine arm month 27 .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>1 . A diagnosis AAV [ granulomatosis polyangiitis microscopic polyangiitis ] , accord definition Chapel Hill Consensus Conference 2 . Current historical PR3/MPO ANCA positivity ELISA 3 . Disease relapse define one major three minor disease activity item Birmingham Vasculitis Activity Score Wegeners ( BVAS/WG ) , patient previously achieve remission follow least 3 month induction therapy , combination glucocorticoid immunosuppressive agent ( cyclophosphamide methotrexate rituximab mycophenolate mofetil ) 4 . Written inform consent 1 . Age &lt; 15 year ( age &lt; 18 year centre treat paediatric patient ) 2 . Exclusions related medication : Previous therapy : 1 . Any biological B cell deplete agent ( rituximab belimumab ) within past 6 month 2 . Alemtuzumab antithymocyte globulin ( ATG ) within last 12 month 3 . IVIg , infliximab , etanercept , adalimumab , abatacept plasma exchange past 3 month 4 . Any investigational agent within 28 day screen , 5 half life investigational drug ( whichever longer ) 3 . Exclusions related general health : 1 . Significant uncontrolled medical disease relate AAV , investigator opinion would preclude patient participation 2 . Presence another multisystem autoimmune disease , include Churg Strauss syndrome , systemic lupus erythematosus , antiGBM disease , cryoglobulinaemic vasculitis , 3 . Any concomitant condition anticipate likely require great 4 week per year oral systemic glucocorticoid use would preclude compliance glucocorticoid protocol ( e.g . poorlycontrolled asthma , COPD , psoriasis , inflammatory bowel disease ) . 4 . History severe allergic anaphylactic reaction humanise murine chimeric monoclonal antibody 5 . Known infection HIV ( HIV test requirement trial entry ) ; past current history hepatitis B virus hepatitis C virus infection . 6 . Ongoing recent ( last 12 month ) evidence active tuberculosis know active infection ( screen tuberculosis part `` standard care‟ patient establish AAV ) evidence untreated latent tuberculosis . Screening tuberculosis per local practice . 7 . History malignancy within past five year evidence persistent malignancy , except fully excise basal cell squamous cell carcinoma skin , cervical carcinoma situ treat excised curative procedure . 8 . Pregnancy inadequate contraception premenopausal woman 9 . Breast feed lactate 4 . Exclusion criterion related laboratory parameter : 1 . Bone marrow suppression evidence total white count &lt; 4 x109/l , haemoglobin &lt; 7 gm/dl platelet count &lt; 100,000/μl 2 . Aspartate aminotransferase alanine aminotransferase amylase &gt; 2.5 time upper limit normal , unless attribute vasculitis</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>vasculitis</keyword>
	<keyword>ANCA vasculitis</keyword>
	<keyword>microscopic polyangiitis</keyword>
	<keyword>granulomatosis</keyword>
	<keyword>Wegener 's</keyword>
	<keyword>AAV</keyword>
	<keyword>vasculitides</keyword>
</DOC>